Apraglutide

Unassigned

New Medicines

Short bowel syndrome in adults

Information

New molecular entity
VectivBio
VectivBio

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials
Yes
Yes

Category

Long-acting GLP-2 analogue, given by weekly SC injection.
European prevalence of SBS is estimated to be 3.4 per 100,000 [1].
Short bowel syndrome in adults
Subcutaneous injection